#BEGIN_DRUGCARD DB03635

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C2H6O3S

# Chemical_IUPAC_Name:
ethanesulfonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Ethanesulfonic Acid

# HET_ID:
ESA

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C2H6O3S/c1-2-6(3,4)5/h2H2,1H3,(H,3,4,5)

# InChI_Key:
InChIKey=CCIVGXIOQKPBKL-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3635

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
110.132

# Molecular_Weight_Mono:
110.003764748

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1RDF

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.7

# Predicted_LogS:
-0.32

# Predicted_Water_Solubility:
5.24e+01 g/l

# Primary_Accession_No:
DB03635

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
11668

# PubChem_Substance_ID:
46504764

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01359

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCS(O)(=O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:27 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
Not Available

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
phnX

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Involved in catalytic activity

# Drug_Target_1_General_References:
10956028	Morais MC, Zhang W, Baker AS, Zhang G, Dunaway-Mariano D, Allen KN: The crystal structure of bacillus cereus phosphonoacetaldehyde hydrolase: insight into catalysis of phosphorus bond cleavage and catalytic diversification within the HAD enzyme superfamily. Biochemistry. 2000 Aug 29;39(34):10385-96.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
5363

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
30060

# Drug_Target_1_Name:
Phosphonoacetaldehyde hydrolase

# Drug_Target_1_Number_of_Residues:
264

# Drug_Target_1_PDB_ID:
1RQN

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00702	Hydrolase

# Drug_Target_1_Protein_Sequence:
>Phosphonoacetaldehyde hydrolase
MKIEAVIFDWAGTTVDYGCFAPLEVFMEIFHKRGVAITAEEARKPMGLLKIDHVRALTEM
PRIASEWNRVFRQLPTEADIQEMYEEFEEILFAILPRYASPINGVKEVIASLRERGIKIG
STTGYTREMMDIVAKEAALQGYKPDFLVTPDDVPAGRPYPWMCYKNAMELGVYPMNHMIK
VGDTVSDMKEGRNAGMWTVGVILGSSELGLTEEEVENMDSVELREKIEVVRNRFVENGAH
FTIETMQELESVMEHIEKQELIIS

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Involved in phosphonate degradation

# Drug_Target_1_SwissProt_ID:
O31156

# Drug_Target_1_SwissProt_Name:
PHNX_BACCE

# Drug_Target_1_Synonyms:
EC 3.11.1.1
Phosphonatase
Phosphonoacetaldehyde phosphonohydrolase

# Drug_Target_1_Theoretical_pI:
4.50

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Secreted protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
PPBP

# Drug_Target_2_GenBank_ID_Gene:
M54995

# Drug_Target_2_GenBank_ID_Protein:
181176

# Drug_Target_2_GeneCard_ID:
PPBP

# Drug_Target_2_Gene_Name:
PPBP

# Drug_Target_2_Gene_Sequence:
>387 bp
ATGAGCCTCAGACTTGATACCACCCCTTCCTGTAACAGTGCGAGACCACTTCATGCCTTG
CAGGTGCTGCTGCTTCTGTCATTGCTGCTGACTGCTCTGGCTTCCTCCACCAAAGGACAA
ACTAAGAGAAACTTGGCGAAAGGCAAAGAGGAAAGTCTAGACAGTGACTTGTATGCTGAA
CTCCGCTGCATGTGTATAAAGACAACCTCTGGAATTCATCCCAAAAACATCCAAAGTTTG
GAAGTGATCGGGAAAGGAACCCATTGCAACCAAGTCGAAGTGATAGCCACACTGAAGGAT
GGGAGGAAAATCTGCCTGGACCCAGATGCTCCCAGAATCAAGAAAATTGTACAGAAAAAA
TTGGCAGGTGATGAATCTGCTGATTAA

# Drug_Target_2_General_Function:
Involved in cytokine activity

# Drug_Target_2_General_References:
10877842	Krijgsveld J, Zaat SA, Meeldijk J, van Veelen PA, Fang G, Poolman B, Brandt E, Ehlert JE, Kuijpers AJ, Engbers GH, Feijen J, Dankert J: Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J Biol Chem. 2000 Jul 7;275(27):20374-81.
11468158	Zhang C, Thornton MA, Kowalska MA, Sachis BS, Feldman M, Poncz M, McKenzie SE, Reilly MP: Localization of distal regulatory domains in the megakaryocyte-specific platelet basic protein/platelet factor 4 gene locus. Blood. 2001 Aug 1;98(3):610-7.
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
1826003	Majumdar S, Gonder D, Koutsis B, Poncz M: Characterization of the human beta-thromboglobulin gene. Comparison with the gene for platelet factor 4. J Biol Chem. 1991 Mar 25;266(9):5785-9.
2007144	Clark-Lewis I, Moser B, Walz A, Baggiolini M, Scott GJ, Aebersold R: Chemical synthesis, purification, and characterization of two inflammatory proteins, neutrophil activating peptide 1 (interleukin-8) and neutrophil activating peptide. Biochemistry. 1991 Mar 26;30(12):3128-35.
2406364	Walz A, Baggiolini M: Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. J Exp Med. 1990 Feb 1;171(2):449-54.
2423119	Holt JC, Harris ME, Holt AM, Lange E, Henschen A, Niewiarowski S: Characterization of human platelet basic protein, a precursor form of low-affinity platelet factor 4 and beta-thromboglobulin. Biochemistry. 1986 Apr 22;25(8):1988-96.
2522778	Walz A, Baggiolini M: A novel cleavage product of beta-thromboglobulin formed in cultures of stimulated mononuclear cells activates human neutrophils. Biochem Biophys Res Commun. 1989 Mar 31;159(3):969-75.
2713489	Wenger RH, Wicki AN, Walz A, Kieffer N, Clemetson KJ: Cloning of cDNA coding for connective tissue activating peptide III from a human platelet-derived lambda gt11 expression library. Blood. 1989 May 1;73(6):1498-503.
2783111	Castor CW, Walz DA, Ragsdale CG, Hossler PA, Smith EM, Bignall MC, Aaron BP, Mountjoy K: Connective tissue activation. XXXIII. Biologically active cleavage products of CTAP-III from human platelets. Biochem Biophys Res Commun. 1989 Sep 15;163(2):1071-8.
6572368	Castor CW, Miller JW, Walz DA: Structural and biological characteristics of connective tissue activating peptide (CTAP-III), a major human platelet-derived growth factor. Proc Natl Acad Sci U S A. 1983 Feb;80(3):765-9.
7706245	Malkowski MG, Wu JY, Lazar JB, Johnson PH, Edwards BF: The crystal structure of recombinant human neutrophil-activating peptide-2 (M6L) at 1.9-A resolution. J Biol Chem. 1995 Mar 31;270(13):7077-87.
77677	Begg GS, Pepper DS, Chesterman CN, Morgan FJ: Complete covalent structure of human beta-thromboglobulin. Biochemistry. 1978 May 2;17(9):1739-44.
7890771	Ehlert JE, Petersen F, Kubbutat MH, Gerdes J, Flad HD, Brandt E: Limited and defined truncation at the C terminus enhances receptor binding and degranulation activity of the neutrophil-activating peptide 2 (NAP-2). Comparison of native and recombinant NAP-2 variants. J Biol Chem. 1995 Mar 17;270(11):6338-44.
8034022	Kungl AJ, Machius M, Huber R, Schwer C, Lam C, Aschauer H, Ehn G, Lindley IJ, Auer M: Purification, crystallization and preliminary X-ray diffraction analysis of recombinant human neutrophil-activating peptide 2 (rhNAP-2). FEBS Lett. 1994 Jun 27;347(2-3):300-3.
8950790	Piccardoni P, Evangelista V, Piccoli A, de Gaetano G, Walz A, Cerletti C: Thrombin-activated human platelets release two NAP-2 variants that stimulate polymorphonuclear leukocytes. Thromb Haemost. 1996 Nov;76(5):780-5.

# Drug_Target_2_HGNC_ID:
HGNC:9240

# Drug_Target_2_HPRD_ID:
07171

# Drug_Target_2_ID:
1258

# Drug_Target_2_Locus:
4q12-q13

# Drug_Target_2_Molecular_Weight:
13894

# Drug_Target_2_Name:
Platelet basic protein

# Drug_Target_2_Number_of_Residues:
128

# Drug_Target_2_PDB_ID:
1F9P

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00048	IL8

# Drug_Target_2_Protein_Sequence:
>Platelet basic protein precursor
MSLRLDTTPSCNSARPLHALQVLLLLSLLLTALASSTKGQTKRNLAKGKEESLDSDLYAE
LRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKKIVQKK
LAGDESAD

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-34

# Drug_Target_2_Specific_Function:
LA-PF4 stimulates DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by human synovial cells. NAP-2 is a ligand for CXCR1 and CXCR2, and NAP-2, NAP-2(73), NAP-2(74), NAP-2(1-66), and most potent NAP-2(1-63) are chemoattractants and activators for neutrophils. TC-1 and TC-2 are antibacterial proteins, in vitro released from activated platelet alpha-granules. CTAP-III(1-81) is more potent than CTAP-III desensitize chemokine-induced neutrophil activation

# Drug_Target_2_SwissProt_ID:
P02775

# Drug_Target_2_SwissProt_Name:
CXCL7_HUMAN

# Drug_Target_2_Synonyms:
CXCL7
LDGF
Leukocyte-derived growth factor
MDGF
Macrophage-derived growth factor
PBP
Platelet basic protein precursor
Small inducible cytokine B7

# Drug_Target_2_Theoretical_pI:
9.07

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB03635
